Get the Stockscreener App
6.68
7.80%
0.4835
Pre-market:
6.65
-0.03
-0.45%
Optinose Inc stock is traded at $6.68, with a volume of 192.26K.
It is up +7.80% in the last 24 hours and down -10.95% over the past month.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
See More
Previous Close:
$6.1965
Open:
$6.32
24h Volume:
192.26K
Relative Volume:
3.70
Market Cap:
$1.01B
Revenue:
$75.67M
Net Income/Loss:
$-31.15M
P/E Ratio:
-13.36
EPS:
-0.5
Net Cash Flow:
$-39.79M
1W Performance:
+16.95%
1M Performance:
-10.95%
6M Performance:
-57.18%
1Y Performance:
-65.48%
1-Day Range:
$5.71
$6.97
1-Week Range:
$5.25
$6.97
52-Week Range:
$4.815
$31.50
Optinose Inc Stock (OPTN) Company Profile
Name
Optinose Inc
Sector
Phone
267-364-3500
Address
777 TOWNSHIP LINE ROAD, YARDLEY, PA
Compare OPTN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OPTN
Optinose Inc
|
6.68 | 1.01B | 75.67M | -31.15M | -39.79M | -0.2777 |
|
ZTS
Zoetis Inc
|
162.93 | 73.51B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.54 | 43.13B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.24 | 41.98B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.04 | 24.97B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.45 | 14.86B | 15.05B | -883.30M | 1.89B | -0.74 |
Optinose Inc Stock (OPTN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Aug-21-23 | Initiated | Lake Street | Buy |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Dec-18-19 | Initiated | Cowen | Outperform |
| Aug-08-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Optinose Inc Stock (OPTN) Latest News
OptiNose stock hits 52-week high of $6.2 amid market fluctuations - Investing.com Nigeria
Midday Market Movers: Biggest Stock Declines of the Day – Stock Market - HPBL
OptiNose stock hits 52-week high of $6.2 amid market fluctuations By Investing.com - Investing.com South Africa
Stock market news: Coeptis Therapeutics Holdings -96.03%, OptiNose -93.07% among biggest losers during mid day trading - Business Upturn
OptiNose (NASDAQ:OPTN) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Stock market today: Coeptis Therapeutics Holdings -95.79%, OptiNose -93.64% among biggest losers in early trading - Business Upturn
Optinose Announces 1-for-15 Reverse Stock Split - MSN
Optinose to effect 1-for-15 reverse stock split for Nasdaq compliance - MSN
OptiNose, Inc. (NASDAQ:OPTN) Sees Large Decline in Short Interest - MarketBeat
Yardley-Based Optinose Implements Reverse Stock Split to Boost Share Price, Avoid NASDAQ Delisting - BUCKSCO.Today
OptiNose Stock Scheduled to Reverse Split on Tuesday, December 31st (NASDAQ:OPTN) - Defense World
Optinose to enact 1-for-15 reverse stock split under threat of Nasdaq delisting - The Business Journals
Optinose announces reverse stock split to meet Nasdaq rules - Investing.com
Optinose (OPTN) Announces 1-for-15 Reverse Stock Split to Maintain Nasdaq Listing Compliance - StockTitan
Optinose CEO Mahmoud Ramy A sells $2,030 in common stock By Investing.com - Investing.com South Africa
Optinose CEO Mahmoud Ramy A sells $2,030 in common stock - Investing.com India
Optinose chief legal officer sells shares worth $1,342 By Investing.com - Investing.com Australia
Optinose chief legal officer sells shares worth $1,342 - Investing.com
SEC Form DEF 14A filed by OptiNose Inc. - Quantisnow
Form DEF 14A OptiNose, Inc. For: Dec 12 - StreetInsider.com
Former CEO Launches Wayne-based Enginuity Rx, Integrated Provider of End-to-End Digital Care - MSN
Optinose to Present at Piper Sandler Healthcare Conference - MyChesCo
SEC Form PRE 14A filed by OptiNose Inc. - Quantisnow
Optinose to Present at Piper Sandler Healthcare Conference, Showcasing ENT Portfolio | OPTN Stock News - StockTitan
Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Former Optinose CEO Peter Miller comes out of retirement to launch new startup - The Business Journals
OptiNose, Inc. (NASDAQ:OPTN) Might Not Be As Mispriced As It Looks After Plunging 31% - Simply Wall St
91,084 Shares in OptiNose, Inc. (NASDAQ:OPTN) Acquired by GSA Capital Partners LLP - Defense World
Stonepine Capital Management, LLC Increases Stake in OptiNose Inc - GuruFocus.com
OptiNose (OPTN) Reports Break-Even Earnings for Q3 - MSN
OptiNose (STU:0OP) Owner Earnings per Share (TTM) : -0.31 (As of Sep. 2024) - GuruFocus.com
Optinose to Announce Q3 2024 Financial Results with Investor Call - MSN
OptiNose (STU:0OP) 5-Year EBITDA Growth Rate : 41.10% (As of Sep. 2024) - GuruFocus.com
OptiNose stock plunges to 52-week low at $0.37 amid market challenges - Investing.com
FY2024 EPS Estimates for OptiNose Increased by HC Wainwright - Defense World
Earnings Release: Here's Why Analysts Cut Their OptiNose, Inc. (NASDAQ:OPTN) Price Target To US$3.50 - Simply Wall St
OptiNose, Inc. (NASDAQ:OPTN) Just Reported, And Analysts Assigned A US$3.50 Price Target - Yahoo Finance
FY2024 EPS Estimates for OptiNose Raised by HC Wainwright - MarketBeat
Great Point Partners LLC Bolsters Position in OptiNose Inc - GuruFocus.com
HC Wainwright Reaffirms Buy Rating for OptiNose (NASDAQ:OPTN) - Defense World
OptiNose Third Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.083 loss in 3Q 2023) - Yahoo Finance
Optinose stock target down as analyst cites challenges in Xhance sales guidance - Investing.com UK
Optinose Reports Q3 2024 Financial Results, Highlights XHANCE Performance - MyChesCo
OptiNose (NASDAQ:OPTN) Given Buy Rating at HC Wainwright - MarketBeat
OptiNose, Inc. (NASDAQ:OPTN) Q3 2024 Earnings Call Transcript - Insider Monkey
OptiNose Inc (OPTN) Q3 2024 Earnings Call Highlights: Revenue Gr - GuruFocus.com
OptiNose Inc (OPTN) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Revised Guidance - Yahoo Finance
FMR LLC's Strategic Acquisition of OptiNose Inc Shares - GuruFocus.com
Optinose Inc Stock (OPTN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):